NMB04
NMB04 is a recombinant anti-Human CD257 (BAFF) (BLyS) antibody. NMB04 binds with specificity and high affinity to soluble and membrane-bound Blys, and blocks Blys binding to receptors TACI, BCMA, and BR-3. NMB04 can be used for the research of autoimmune diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Human
NMB04 (1 h) binds to soluble human Blys with high affinity, as indicated by an EC50 of 0.023 nM[1].
NMB04 binds to soluble human Blys with a high sub-nanomolar affinity (KD = 7.38×10-10 M)[1].
NMB04 (1 h) binds to membrane-bound human Blys expressed on 293C18 cells with an EC50 of 0.13 nM[1].
NMB04 (1 h) potently inhibits Blys binding to human BR3, TACI, and BCMA receptors with IC50 values of 0.12 nM, 0.25 nM, and 0.12 nM respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | AUC0-∞ | T1/2 |
|---|---|---|---|---|
| Cynomolgus Monkey[1] | 5 mg/kg | i.v. | 17456 μg·h/mL | 153.83 h |
NMB04 (5 mg/kg; i.v.; once weekly; 4 weeks) inhibits CD20+ B cells in mesenteric lymph nodes and mature CD21+ B cells in peripheral blood in cynomolgus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C mice (female)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; on days 1 and 3
-
Result:Completely attenuated the increase in B220+/ThB+ mature splenic B cell population induced by human Blys.
Reduced the proportion of B220+/ThB+ cells to levels comparable to control group.
-
Animal Model:Cynomolgus Monkeys (2-4 years old, male)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; once weekly; 4 weeks
-
Result:Reduced the CD20+ B cell population in mesenteric lymph nodes to 18.31%.
Significantly inhibited the proliferation of mature CD21+ B cells in peripheral blood.
TNFSF13B/BAFF/CD257
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NMB04 Related Classifications
HY-P992424 Related Classifications
Powered by Bioz